Market News How it works Learn FAQ
| RCT 0.0796 4.60% | NU 12.69 -16.29% | EWZ 34.43 -19.16% | BBD 2.935 -27.89% | TGL 0.2399 8.31% | AZTR 1.6199 126.56% | ITUB 7.75 -19.86% | NVD 3.9801 -5.01% | XP 15.9 -47.71% | SRTM 0.2985 -30.63% | WFF 0.0918 14.75% | SHFS 0.0943 -28.78% | SPCX 148.07 0.39% | PBR 22.515 -13.93% | SOXL 92.02 10.12% | VALE 11.96 -3.55% | CLRO 5.015 54.31% | INTC 91.38 5.08% | TSLL 10.875 11.42% | NVDA 216.37 2.56% | GCDT 0.1444 -18.00% | NOK 8.735 7.31% | NWGL 0.089 8.54% | BITO 10.66 -1.57% | SOXS 47.14 -10.14% | CRWV 56.4528 4.09% | RWM 14.485 -0.45% | JBLU 2.345 -10.67% | GPUS 0.1808 7.05% | ABEV 2.835 -14.09% | TSLG 5.44 11.70% | SGRY 23.245 47.59% | AAL 12.2501 1.16% | IREN 25.945 4.18% | INTR 4.6799 -34.91% | SBS 4.69 -26.72% | QID 14.175 -2.58% | TQQQ 68.805 3.79% | RBNE 0.17 -10.53% | T 20.9 -0.14% | SPDN 8.485 -0.64% | TSLA 393.715 5.77% | RIG 6.455 0.70% | WULF 12.225 7.99% | NFLX 63.745 -3.20% | SID 0.9078 -23.07% | LUCD 0.52 26.52% | GRAB 2.692 -3.51% | XTND 2.235 26.27% | PLUG 1.39 0.72%
TSTherapeutic Solutions International, Inc. logo

Therapeutic Solutions International, Inc. (TSOI)

Other OTC · Currency in USD
$0.00 ▲ +0.00 (+0.00%)
At close: Oct 23, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.00
Open
$0.00
Day's Range
$0.00 – $0.00
52 Week Range
$0.00 – $0.00
Volume
262,500
Avg. Volume
386,712
Market Cap
$512.27K
Beta (5Y Monthly)
0.24
PE Ratio (TTM)
--
EPS (TTM)
-$0.00
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Therapeutic Solutions International, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
3
CEO
Timothy George Dixon

Therapeutic Solutions International, Inc. is dedicated to modulating the immune system to address a diverse array of serious conditions. The company formulates immune-modulatory agents targeting cancers, schizophrenia, suicidal ideation, and various neurological disorders like traumatic brain injury and chronic traumatic encephalopathy, alongside lung pathologies and general health maintenance. Its premier product, QuadraMune, is a patented, synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone, engineered to amplify natural killer cell activity and foster healthy cytokine production.

Earnings

DateEst.Actual
Nov 20, 2024–-$0.00
Aug 21, 2024$1.54-$0.00Miss
May 30, 2024–-$0.00
Apr 16, 2024–-$0.00
Nov 14, 2023–-$0.18
Aug 21, 2023–-$0.00

Get free alerts on TSOI and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.